This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Meanwhile, genetic association studies in humans show that the same protein-truncating variants (PTVs) in the PPP1R3A gene that lead to ~65% reduction in muscle glycogen in humans do not affect cardiac parameters including left ventricle wall thickness, left ventricular ejection fraction, exercise output, maximum heart rate, QT interval, or serum glucose, (..)
Matthew subsequently put his computationalchemistry skills to use in the defence sector. Following a second stint in defence, he joined Cresset in 2022, working to develop, source and evaluate new computational techniques for Cresset’s software.
Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computationalchemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.
Drug discovery scientists, especially those with backgrounds in computationalchemistry and cheminformatics, don’t always appreciate the importance of controlling exposure and the uncertainty in intracellular concentration always makes for a good stock question for speakers and panels of experts.
The premise at the time was that putting computationalchemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computationalchemistry, and do all the wet work at CROs. It did just that.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content